Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection

NCT04481633

CompletedNA

Sponsor: University Hospital, Toulouse

Conditions: COVID-19

Interventions: COVID 19 serology, COVID 19 Self-Questionnaire

Countries: France

There is a pandemic in the world by COVID-19. Currently, the pharmacological curative or prophylactic treatments for this infection are not known. Recent studies have suggested that Hydroxy-Chloroquine could be effective in vitro and in vivo against COVID-19. The main objective of this study is to assess in patients with autoimmune disease treated with long course Hydroxy-Chloroquine initiated before the pandemic COVID-19 had an independent protective effect on the risk or the severity of infection with COVID-19.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

Group with hydroxychloroquine treatment (HC +):

* LED/SG diagnosed
* Treatment with Hydroxy-Chloroquine in the 3 months before and during the outbreak at COVID 19, at least in December 2019. Patients may have treatment with immunosuppressants in combination with Hydroxy-Chloroquine.
* COVID19 diagnostic questionnaire and available serology result.

Group without hydroxychloroquine treatment (HC-) :

* No Hydroxy-Chloroquine intake for more than 12 months

  --\> HC- without an immunosuppressant
* Viral hepatitis C cured for more than 12 months or primitive bile cholangitis (CBP) whose diagnosis is based on international criteria.
* Non-significant liver fibrosis assessed either by historical histology or by fibroscan with non-significant liver fibrosis Metavir - F3 (at last available examination)
* No Hydroxy-Chloroquine, or immunosuppressants have been taken for more than 12 months.
* COVID19 diagnostic questionnaire and COVID19 serology result available.

  --\>HC- with an immunosuppressant
* Diagnosis of LED/SG according to the CAB criteria revised in 1997 or autoimmune hepatitis according to the international criteria validated in 2008.
* Patients treated with immunosuppressants for at least three months before the start of the pandemic at COVID 19, at least since December 2019.
* COVID19 diagnostic questionnaire and available serology result.

Exclusion Criteria:

* Anti-CD20 or Cyclophosphamide taken during the six months prior to the completion of the COVID 19 serology.
* Refusal of a blood test for antibodies to COVID-19.
* Protected adults
* Pregnant or breastfeeding women.
* Lack of health insurance coverage
Locations (12)
  • Limoges, France
  • Montpellier, France
  • Paris, France
  • Paris, France
  • Pessac, France
  • Pessac, France
  • Toulouse, France
  • Toulouse, France
  • Toulouse, France
  • Toulouse, France
  • Toulouse, France
  • Toulouse, France